Cross-border teams from Sullivan & Cromwell and Latham & Watkins have landed the lead roles on the $40bn takeover of Allergan’s generic-making business by Teva that has seen the Israeli pharmaceutical powerhouse also abandon its bid for Mylan.
Teva’s $40bn generic-drug buy sees Latham & Watkins and Sullivan & Cromwell lead
